Q-omics provides the consensus-scored SLC24A3 profile across patient tissues and cancer cell-line models. SLC24A3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SLC24A3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SLC24A3 RNA expression shows 17,680 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight BLCA, and UCEC as cancer lineages where SLC24A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC24A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC24A3 survival associations across molecular data types. SLC24A3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC24A3 RNA expression–survival associations across cancer types. High SLC24A3 expression shows unfavorable associations in BLCA and THCA, but favorable associations in LAML, LGG, UCS and MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SLC24A3 RNA expression.
This table summarizes SLC24A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC24A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC24A3 shows lower tumor expression in BLCA, THCA, LUAD, HNSC, UCEC and KICH. The BLCA box plot shows higher SLC24A3 RNA expression in normal versus tumor tissue (log2 FC = −2.855, t-test p < 0.001).
This table shows molecular features associated with SLC24A3 in patient tissues and cancer cell lines. In patient samples, SLC24A3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC24A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
